| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/400 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| WB Predicted band size | 44 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human VSIG8 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于VSIG8抗体的示例参考文献(注：以下内容为模拟示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**: *VSIG8 as a Novel Immune Checkpoint Molecule: Characterization of Its Inhibitory Role in T Cell Activation*
**作者**: Liu, X. et al.
**摘要**: 本研究利用抗VSIG8抗体阻断VSIG8与配体的相互作用，发现其可显著增强T细胞的活化和细胞因子分泌，提示VSIG8可能作为免疫检查点分子，在肿瘤免疫逃逸中发挥作用。
2. **文献名称**: *Development of a Monoclonal Antibody Against VSIG8 for Tumor Microenvironment Analysis*
**作者**: Chen, H. & Wang, Y.
**摘要**: 文章报道了一种高特异性抗VSIG8单克隆抗体的开发，并通过免疫组化证实VSIG8在多种肿瘤基质细胞中高表达，其表达水平与患者预后呈负相关。
3. **文献名称**: *Targeting VSIG8 with Therapeutic Antibodies Attenuates Colitis in Murine Models*
**作者**: Park, S. et al.
**摘要**: 通过抗VSIG8抗体的体内实验，研究发现其可减轻小鼠结肠炎模型的炎症反应，表明靶向VSIG8可能为自身免疫性疾病提供新治疗策略。
4. **文献名称**: *VSIG8 in Immune Regulation: A Review of Antibody-Based Functional Studies*
**作者**: Zhang, L. & Gupta, R.
**摘要**: 综述总结了VSIG8在免疫调控中的功能机制，重点讨论了抗体干预实验揭示的其在调节巨噬细胞极化和Treg细胞功能中的作用。
---
**建议**：如需真实文献，请通过PubMed、Web of Science或Google Scholar检索关键词“VSIG8 antibody”或“VSIG8 immune function”，并筛选近5年研究以获取最新进展。
The V-set and immunoglobulin domain-containing protein 8 (VSIG8) is a transmembrane protein belonging to the immunoglobulin superfamily (IgSF). It is primarily expressed in specific tissues, including the testis and certain immune cells. VSIG8 has garnered interest due to its structural features, such as extracellular V-set and Ig-like domains, which suggest roles in cell-cell interactions and immune regulation. Although its precise biological functions remain under investigation, VSIG8 is hypothesized to participate in immune modulation, potentially influencing T-cell activity or serving as a checkpoint molecule in immune responses.
VSIG8 antibodies are tools developed to detect, quantify, or inhibit VSIG8 in experimental settings. These antibodies enable researchers to study VSIG8's expression patterns, localization, and interactions in healthy and diseased tissues. Recent studies highlight its potential relevance in cancer immunology, where VSIG8 may contribute to tumor immune evasion, akin to other checkpoint proteins like PD-1/PD-L1. Antibodies targeting VSIG8 could thus have therapeutic applications, such as enhancing anti-tumor immunity.
Despite progress, the functional mechanisms of VSIG8 remain partially unresolved. Current research focuses on elucidating its ligands, signaling pathways, and tissue-specific roles. VSIG8 antibodies are critical reagents in these efforts, supporting both basic research and translational studies aimed at exploring VSIG8 as a biomarker or therapeutic target in immune-related disorders.
×
